Skip to content
Tallac Therapeutics, Inc
Tallac Therapeutics, Inc

News

Home
News
2022
July
28

July 28, 2022

In Latest NewsPosted July 28, 2022

Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors

More

Categories

  • Latest News (7)
  • Publication and Data (4)

Recent Posts

  • Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer
  • Tallac Therapeutics Presents Data for Two, First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugates at the Society for Immunotherapy of Cancer 37th Annual Meeting
  • Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors
  • Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for TAC-001, a First-in-Class Toll-like Receptor 9 (TLR9) Agonist Antibody Conjugate for Patients with Advanced Solid Tumors
  • Tallac SITC 2021 Presentation

Archives

  • January 2023
  • November 2022
  • July 2022
  • May 2022
  • October 2021
  • April 2021
  • March 2021
  • December 2020
  • November 2020
Tallac Therapeutics, Inc
  • (650) 866-1966
866 Malcolm Road Suite 100, Burlingame, CA 94010
Linkedin-in Envelope

Copyright © 2020-2023 Tallac Therapeutics, Inc. All Rights Reserved.